The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires C-Src and Metalloproteinase Activation

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jun 27

PMID 26114632

Citations 13

Authors

Susana Garcia-Recio

Eva M Pastor-Arroyo

Mercedes Marin-Aguilera

Vanessa Almendro

Pedro Gascon

Affiliations

Soon will be listed here.

Abstract

Background: Substance P (SP) is a pleiotropic cytokine/neuropeptide that enhances breast cancer (BC) aggressiveness by transactivating tyrosine kinase receptors like EGFR and HER2. We previously showed that SP and its cognate receptor NK-1 (SP/NK1-R) signaling modulates the basal phosphorylation of HER2 and EGFR in BC, increasing aggressiveness and drug resistance. In order to elucidate the mechanisms responsible for NK-1R-mediated HER2 and EGFR transactivation, we investigated the involvement of c-Src (a ligand-independent mediator) and of metalloproteinases (ligand-dependent mediators) in HER2/EGFR activation.

Results And Discussion: Overexpression of NK-1R in MDA-MB-231 and its chemical inhibition in SK-BR-3, BT-474 and MDA-MB-468 BC cells significantly modulated c-Src activation, suggesting that this protein is a mediator of NK-1R signaling. In addition, the c-Src inhibitor 4-(4'-phenoxyanilino)-6,7-dimethoxyquinazoline prevented SP-induced activation of HER2. On the other hand, SP-dependent phosphorylation of HER2 and EGFR decreased substantially in the presence of the MMP inhibitor 1-10, phenanthroline monohydrate, and the dual inhibition of both c-Src and MMP almost abolished the activation of HER2 and EGFR. Moreover, the use of these inhibitors demonstrated that this Src and MMP-dependent signaling is important to the cell viability and migration capacity of HER2+ and EGFR+ cell lines.

Conclusion: Our results indicate that the transactivation of HER2 and EGFR by the pro-inflammatory cytokine/neuropeptide SP in BC cells is a c-Src and MMP-dependent process.

Citing Articles

The tumor-nerve circuit in breast cancer.

Cui Q, Jiang D, Zhang Y, Chen C Cancer Metastasis Rev. 2023; 42(2):543-574.

PMID: 36997828 PMC: 10349033. DOI: 10.1007/s10555-023-10095-1.

The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma.

Munoz M, Arguelles S, Rosso M, Medina R, Covenas R, Ayala A Biomed Res Int. 2022; 2022:6291504.

PMID: 35434136 PMC: 9006081. DOI: 10.1155/2022/6291504.

Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies.

Cervantes-Villagrana R, Albores-Garcia D, Cervantes-Villagrana A, Garcia-Acevez S Signal Transduct Target Ther. 2020; 5(1):99.

PMID: 32555170 PMC: 7303203. DOI: 10.1038/s41392-020-0205-z.

Matrix metalloprotein-triggered, cell penetrating peptide-modified star-shaped nanoparticles for tumor targeting and cancer therapy.

Guo F, Fu Q, Zhou K, Jin C, Wu W, Ji X J Nanobiotechnology. 2020; 18(1):48.

PMID: 32183823 PMC: 7076984. DOI: 10.1186/s12951-020-00595-5.

Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells.

Djeungoue-Petga M, Lurette O, Jean S, Hamel-Cote G, Martin-Jimenez R, Bou M Cell Death Dis. 2019; 10(12):940.

PMID: 31819039 PMC: 6901437. DOI: 10.1038/s41419-019-2134-8.

References

Daub H, Weiss F, Wallasch C, Ullrich A . Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature. 1996; 379(6565):557-60. DOI: 10.1038/379557a0. View

Bost K . Tachykinin-mediated modulation of the immune response. Front Biosci. 2004; 9:3331-2. DOI: 10.2741/1484. View

DeFea K, Vaughn Z, OBryan E, Nishijima D, Dery O, Bunnett N . The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex. Proc Natl Acad Sci U S A. 2000; 97(20):11086-91. PMC: 27152. DOI: 10.1073/pnas.190276697. View

Pierce K, Tohgo A, Ahn S, Field M, Luttrell L, Lefkowitz R . Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. J Biol Chem. 2001; 276(25):23155-60. DOI: 10.1074/jbc.M101303200. View

Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo E, Park S, Mayordomo C . Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res. 2013; 73(21):6424-34. DOI: 10.1158/0008-5472.CAN-12-4573. View

Johnson L, Noble M, Owen D . Active and inactive protein kinases: structural basis for regulation. Cell. 1996; 85(2):149-58. DOI: 10.1016/s0092-8674(00)81092-2. View

Ishizawar R, Miyake T, Parsons S . c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene. 2006; 26(24):3503-10. DOI: 10.1038/sj.onc.1210138. View

Patacchini R, Lecci A, Holzer P, Maggi C . Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sci. 2004; 25(1):1-3. DOI: 10.1016/j.tips.2003.11.005. View

EULER U, Gaddum J . An unidentified depressor substance in certain tissue extracts. J Physiol. 1931; 72(1):74-87. PMC: 1403098. DOI: 10.1113/jphysiol.1931.sp002763. View

10.

Palma C, Maggi C . The role of tachykinins via NK1 receptors in progression of human gliomas. Life Sci. 2000; 67(9):985-1001. DOI: 10.1016/s0024-3205(00)00692-5. View

11.

Friess H, Zhu Z, Liard V, Shi X, Shrikhande S, Wang L . Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Invest. 2003; 83(5):731-42. DOI: 10.1097/01.lab.0000067499.57309.f6. View

12.

Rosso M, Robles-Frias M, Covenas R, Salinas-Martin M, Munoz M . The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol. 2008; 29(4):245-54. DOI: 10.1159/000152942. View

13.

Delcourt N, Bockaert J, Marin P . GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation. Trends Pharmacol Sci. 2007; 28(12):602-7. DOI: 10.1016/j.tips.2007.09.007. View

14.

Olayioye M, Neve R, Lane H, Hynes N . The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000; 19(13):3159-67. PMC: 313958. DOI: 10.1093/emboj/19.13.3159. View

15.

Tian G, Cory M, Smith A, Knight W . Structural determinants for potent, selective dual site inhibition of human pp60c-src by 4-anilinoquinazolines. Biochemistry. 2001; 40(24):7084-91. DOI: 10.1021/bi0100586. View

16.

Biscardi J, Ishizawar R, Silva C, Parsons S . Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res. 2001; 2(3):203-10. PMC: 138776. DOI: 10.1186/bcr55. View

17.

Pennefather J, Lecci A, Candenas M, Patak E, Pinto F, Maggi C . Tachykinins and tachykinin receptors: a growing family. Life Sci. 2004; 74(12):1445-63. DOI: 10.1016/j.lfs.2003.09.039. View

18.

Yamaguchi K, Richardson M, Bigner D, Kwatra M . Signal transduction through substance P receptor in human glioblastoma cells: roles for Src and PKCdelta. Cancer Chemother Pharmacol. 2005; 56(6):585-93. DOI: 10.1007/s00280-005-1030-3. View

19.

Page N . New challenges in the study of the mammalian tachykinins. Peptides. 2005; 26(8):1356-68. DOI: 10.1016/j.peptides.2005.03.030. View

20.

Arthur D, Akassoglou K, Insel P . P2Y2 and TrkA receptors interact with Src family kinase for neuronal differentiation. Biochem Biophys Res Commun. 2006; 347(3):678-82. DOI: 10.1016/j.bbrc.2006.06.141. View